Cancer immunotherapy prediction markets have become one of the richest sources of medical outcome betting — combining FDA approval timelines, trial result binary events, and the commercial implications of breakthrough therapies into markets that attract both patient advocates and sophisticated biotech investors.
CAR-T Cell Therapy Expansion Markets
CAR-T cell therapies have transformed haematological cancer treatment and are now in clinical development for solid tumours — the much larger and commercially more significant application. 'First FDA-approved CAR-T therapy for solid tumour indication by end 2027' is trading at approximately 28% YES, reflecting the genuine scientific progress while pricing in the technical challenges of trafficking T-cells to solid tumour environments.
- →CAR-T solid tumour FDA approval by end 2027: ~28% YES
- →PD-1/PD-L1 checkpoint inhibitor approval in new major indication in 2026: ~70% YES
- →Any cancer type achieves >50% 5-year survival rate improvement from 2020 baseline: ~35% YES
- →mRNA cancer vaccine Phase 3 success reported by end 2027: ~40% YES
- →Cancer immunotherapy global market exceeds $200B by end 2026: ~55% YES
The mRNA cancer vaccine markets are among the most actively watched biomedical prediction markets on Boromarket. The Moderna/Merck collaboration and the BioNTech pipeline both have clear public trial timelines that create verifiable resolution criteria.
FDA Approval Timeline Markets
FDA approval markets for specific drug candidates offer unusually clean resolution criteria but require careful interpretation of trial data. The base rate for FDA approval from Phase 3 commencement is approximately 50-60% depending on indication — a number that prediction markets should anchor to but frequently deviate from due to narrative effects around 'promising' early data.
"The best cancer immunotherapy prediction markets are the ones where Phase 2 data is positive, trial design is strong, and the crowd is still pricing the historical base rate. That gap is where value lives."
— Oncology biotech analyst